SCHEMBL17576271

SCHEMBL17576271

Cc1cc2cc([N+](=O)[O-])ccc2n(C)c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 2/20 0.58
CYP19A1 P11511 1/20 0.57
MAPT P10636 4/20 0.51
ALDH1A1 P00352 5/20 0.47
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 2/20 0.47
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
HPGD P15428 3/20 0.45
HKDC1 Q2TB90 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
LMNA P02545 4/20 0.45
CYP3A4 P08684 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CYP1A2 P05177 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
BRD4 O60885 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20284504 0.83 CYP19A1 (0.56) CYP19A1MAPTALDH1A1TSHRMEN1
SCHEMBL21774736 0.83 CYP19A1 (0.56) CYP19A1MAPTALDH1A1TDP1MEN1
SCHEMBL31036289 0.82 CYP19A1 (0.61) CYP19A1MAPTALDH1A1TDP1TSHR
SCHEMBL3481105 0.82 CYP19A1 (0.61) CYP19A1MAPTALDH1A1TDP1TSHR
SCHEMBL17560658 0.80 BRPF1 (0.69) BRPF1MAPTKMT2AHTTBRD4
SCHEMBL22421730 0.79 MAPT (0.52) CYP19A1MAPTALDH1A1TDP1TSHR
SCHEMBL23320466 0.78 CYP19A1 (0.60) CYP19A1MAPTALDH1A1TDP1TSHR
SCHEMBL30349578 0.78 CYP19A1 (0.56) BRPF1CYP19A1MAPTALDH1A1TDP1
SCHEMBL5443364 0.78 CYP19A1 (0.56) BRPF1CYP19A1MAPTALDH1A1TDP1
SCHEMBL28454121 0.76 ALDH1A1 (0.54) MAPTALDH1A1MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3555063-B1 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2020-09-16 EP disclosed
WO-2018108704-A1 NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-06-21 WO disclosed
US-20170291875-A1 QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS UCL BUSINESS PLC (GB) 2017-10-12 US disclosed
US-20170291875-A1 QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS UCL BUSINESS PLC (GB) 2017-10-12 US disclosed
WO-2016034512-A1 QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS UCL BUSINESS PLC (GB) 2016-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291875-A1 QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS BRD4, BRPF3, BRD3 BRPF1 104/4885CYP19A1 4419/4885MAPT 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.